# A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

> **NCT01380769** · PHASE2 · COMPLETED · sponsor: **NewLink Genetics Corporation** · enrollment: 157 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** CRLX101
- **OTHER:** Best Supportive Care

## Key facts

- **NCT ID:** NCT01380769
- **Lead sponsor:** NewLink Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2013-02
- **Final completion:** 2014-10
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01380769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01380769, "A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01380769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*